Piramal Pharma Ltd. to invest minority stake in Yapan Bio, an India-based CDMO providing expertise in biologics and vaccines


Piramal Pharma Solutions Adds New Technologies and Capabilities in Large Molecules, Including Vaccines and Gene Therapy, to Global Offering

INR101.77cr investment in biologics reflects the company’s global commitment to this rapidly growing segment of the pharmaceutical industry

Mumbai, India, December 21, 2021 / CNW / – Piramal Pharma Limited (PPL) today announced an investment of INR101.77cr in Yapan Bio Pvt Ltd (“Yapan”) from Hyderabad, India, increasing the capacities of its Contract Development and Manufacturing Organization (CDMO), Piramal Pharma Solutions (PPS) activity. PPL holds 27.78% of the company’s capital as a result of this investment. As PPS continues to build its capabilities and position itself as a leading CDMO, this acquisition marks a significant addition to PPS ‘global capabilities in the development and manufacture of large molecules for human clinical trials.


Yapan Bio provides process development, scale-up and cGMP-compliant manufacturing of vaccines and biologics / biotherapeutics, including high containment product classes (up to BSL-2 +), vaccines recombinant, RNA / DNA vaccines, gene therapies, monoclonal antibodies, therapeutic proteins and other complex biologicals. Yapan’s turnover for fiscal year 21 was INR 12.4 cr. The company has already achieved a turnover of 11.8 cents INR for the first half of fiscal year 22 and is poised for rapid growth in response to strong market demand.

The investment in Yapan Bio enables PPS to expand its service offering in the CDMO space of fast growing biologics. The capabilities of biologics may be synergistic with the antibody-drug conjugation capabilities of the company; specifically, for customers who prefer the speed and simplicity advantages of an integrated program that involves development, fabrication, mating and filling finishing. PPS currently offers integrated payload, conjugation and fill-finish services, and the addition of antibody capabilities enhances this offering.

Nandini Piramal, President, Piramal Pharma Limited, said, “The expertise found at Yapan will help Piramal provide its existing customers with broader capabilities for the development and manufacture of large molecules. This investment further supports our growth strategy for Piramal Pharma. “

Peter DeYoung, CEO, Pharmaceutical Solutions, Piramal Pharma Limited, said, “Over the past decade, biologics and accompanying development services have been the fastest growing segments of the CDMO market. This investment, together with our state-of-the-art facility in Grangemouth, UK, in antibody-drug conjugations and our sterile fill / finish capabilities in Lexington, United States, demonstrates our commitment to developing our service offerings in the field of large molecule CDMOs. “

Atin Tomar and Nirav Desai, CEO and COO of Yapan, said: “We are very excited about this transaction and are confident that PPS is the ideal partner to lead the business through its next phase of growth. Yapan employees and customers, who are key stakeholders in our business, will most certainly benefit from PPS ‘expertise in delivering integrated services on a global scale. “

In today’s market, many innovative pharmaceutical companies are looking for CDMOs to meet their biologics development and manufacturing needs. PPS expects that the addition of these capabilities and expertise will allow the company to further enhance its offerings in this fast growing and attractive industry.

Trilegal acted as legal counsel to PPL in connection with this transaction. Torreya Partners India LLP served as financial advisor and Samisti Legal LLP served as legal advisers to Yapan for this transaction.

About Piramal Pharma Solutions:

Piramal Pharma Solutions (PPS) is a contract development and manufacturing (CDMO) organization providing end-to-end development and manufacturing solutions throughout the drug lifecycle. We serve our customers through an integrated global network of facilities in North America, Europe, and Asia. This enables us to offer a full range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial API supply and finished dosage forms. We also provide specialty services such as the development and manufacture of high potency APIs, antibody-drug conjugations, sterile fill / finish, peptide products and services, and strong oral solid drug products. Our background as a trusted service provider with experience in various technologies makes us a partner of choice for innovative and generic companies around the world.

For more information, please visit: www.piramalpharmasolutions.com | Twitter | LinkedIn

About Piramal Pharma Ltd.

Piramal Pharma Limited (PPL) offers a differentiated product and service portfolio with end-to-end manufacturing capabilities in 15 global facilities and a global distribution network in over 100 countries. PPL comprises: Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics company, and India Consumer Healthcare, selling over-the-counter products. PPS provides end-to-end development and manufacturing solutions through an integrated global network of facilities throughout the drug lifecycle to innovative and generic companies. PCC’s complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, analgesics and injectable anesthetics, injectable anti-infectives and other therapies. The Indian Consumer Healthcare activity is one of the main players in India in the personal care space, with brands established in the Indian consumer health market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulation market. In October 2020, the company received a growth capital investment from the Carlyle Group.

For more information visit: www.piramal.com | Facebook | Twitter | LinkedIn

About Yapan Bio Pvt Ltd

Yapan Bio Pvt Ltd, located in Genome Valley in Hyderabad, was founded by Atin Tomar and Nirav Desai, both with ~ 40 years of combined experience in the biotechnology industry, globally, specializing in the development, manufacture and marketing of vaccines and biologics / biotherapeutics. Yapan Bio is a contracted process development and manufacturing (CDMO) organization providing process development, scale-up and manufacture of GMP vaccine and biologics / biotherapeutics complaints for human clinical trials across the world. Yapan’s capabilities include development facilities and GMPs for high containment product classes (up to BSL-2 +).

For more information visit https://www.yapanbio.com



Show original content:https://www.prnewswire.com/news-releases/piramal-pharma-ltd-to-invest-minority-stake-in-yapan-bio-india-based-cdmo-providing-expertise-in-biologics-and- vaccines-301448738.html

SOURCE Piramal Pharma Solutions



Show original content: http://www.newswire.ca/en/releases/archive/December2021/21/c2457.html


About Johnnie Gross

Check Also


Shenzhen, China, November 14, 2022 /CNW/ — As an Exclusive cryptocurrency Partner of the Rugby …